Co-Morbidities and Adverse Drug Reactions in HIV
Workshop publications

Sample papers arising from abstracts presented during International Comorbidities Workshops*

*list not exhaustive

1999 (San Diego, 1st Workshop)

Walli R et a., AIDS. 1998 Oct 22;12(15):F167-73
https://www.ncbi.nlm.nih.gov/pubmed/9814858  (PIs and insulin resistance)

Engelson ES et al. J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):379-91
https://www.ncbi.nlm.nih.gov/pubmed/12138344  (early study on growth hormone for visceral fat accumulation)

Carr A et al. Lancet. 2003 Mar 1;361(9359):726-35
https://www.ncbi.nlm.nih.gov/pubmed/12620736  (lipodystrophy case definition, stimulated by the cohort studies presented at the first meeting and the example of rheumatology presented by MH Liang from Havard)

Brinkman K et al. Lancet. 1999 Sep 25;354(9184):1112-5
https://www.ncbi.nlm.nih.gov/pubmed/?term=10509516 (mitochondrial toxicity induced by nucleoside-analogue reverse)

Carr A et al. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):571-6
https://www.ncbi.nlm.nih.gov/pubmed/?term=12902800 (objective lipodystrophy severity grading scale)

Back to top

2000 (Toronto)

Noor MA etl. AIDS. 2001 May 4;15(7):F11-8.
https://www.ncbi.nlm.nih.gov/pubmed/11399973 (first study showing impairment of insulin sensitivity in HIV)

Tebas P et al. AIDS. 2000 Mar 10;14(4):F63-7
https://www.ncbi.nlm.nih.gov/pubmed/10770534 (early studies reporting effects on bone)

Carr A et al. AIDS. 2001 Apr 13;15(6):703-9
https://www.ncbi.nlm.nih.gov/pubmed/11371684 (cohort studies demonstrating lipodystrophy in European, American, African and Asian patients)

Lichtenstein KA et al. AIDS. 2001 Jul 27;15(11):1389-98
https://www.ncbi.nlm.nih.gov/pubmed/11504960 (Clinical assessment of HIV-associated lipodystrophy in an ambulatory population)

Martinez E et al. Lancet. 2001 Feb 24;357(9256):592-8
https://www.ncbi.nlm.nih.gov/pubmed/11558485 (Risk of lipodystrophy in HIV-1-infected patients treated with PIs)

Paton NI et al. Clin Infect Dis. 2002 Nov 15;35(10):1244-9. Epub 2002 Oct 21
https://www.ncbi.nlm.nih.gov/pubmed/12410485 (prevalence and psychological impact of lipodystrophy in a cohort of HIV-infected Asian patients)

Back to top

2001 (Athens)

Noor Ma et al. AIDS. 2002 Mar 29;16(5):F1-8
https://www.ncbi.nlm.nih.gov/pubmed/11964551  (placebo controlled trial on indinavir and insulin resistance)

Hadigan C et al. Metabolism. 2002 Sep;51(9):1143-7
https://www.ncbi.nlm.nih.gov/pubmed/12200758  (increased lipolysis in lipodystrophy)

Dubé MP et al. Clin Infect Dis. 2002 Aug 15;35(4):475-81
https://www.ncbi.nlm.nih.gov/pubmed/12145733  (one of the first prospective antiretroviral studies assessing body composition and metabolic aspects)

Walker UA et al. AIDS. 2002 Nov 8;16(16):2165-73
https://www.ncbi.nlm.nih.gov/pubmed/12409738  (increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors)

Shikuma CM et al. AIDS. 2001 Sep 28;15(14):1801-9
https://www.ncbi.nlm.nih.gov/pubmed/11579242  (mitochondrial toxicity demonstrated in fat biopsies from patients)

Martinez E et al. Antivir Ther. 2003 Oct;8(5):403-10
https://www.ncbi.nlm.nih.gov/pubmed/14640387  (first studies looking for medical therapies)

Schwarz JM et al. J Clin Endocrinol Metab. 2002 Feb;87(2):942
https://www.ncbi.nlm.nih.gov/pubmed/11836345 (effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation)

Caron M etal. Diabetes. 2001 Jun;50(6):1378-88
https://www.ncbi.nlm.nih.gov/pubmed/11375339 (indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization and induces insulin resistance)

Mauss S & Schmutz G HIV Med. 2001 Jan;2(1):59-60
https://www.ncbi.nlm.nih.gov/pubmed/11737377 (L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome)

Back to top

2002 (San Diego)

Nolan D et al. AIDS. 2003 Jun 13;17(9):1329-38
https://www.ncbi.nlm.nih.gov/pubmed/12799554  (mitochondrial toxicity and NNRTIs in fat biopsies)

Lonergan JT et al. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-42
https://www.ncbi.nlm.nih.gov/pubmed/15220700 (switch from ZDV to ABC prevents recurrence of hyperlactatemia)

Dubé MP et al. AIDS. 2005 Nov 4;19(16):1807-18
https://www.ncbi.nlm.nih.gov/pubmed/16227788 (early prospective body comp study)

Bastard JP et al. Lancet. 2002 Mar 23;359(9311):1026-31
https://www.ncbi.nlm.nih.gov/pubmed/11937183 (association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance)

Mauss S et al. HIV Med. 2002 Jan;3(1):49-55
https://www.ncbi.nlm.nih.gov/pubmed/12059951 (risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment)

Back to top

2003 (Paris)

Driscoll SD et al, AIDS. 2004 Feb 20;18(3):465-73
https://www.ncbi.nlm.nih.gov/pubmed/15090799 (effect of metformin and exercise on body composition)

Koster JC et al. Diabetes. 2003 Jul;52(7):1695-1700
https://www.ncbi.nlm.nih.gov/pubmed/12829635 (mechanism and underlying effect of PI on insulin release)

Hadigan C et al. Ann Intern Med. 2004 May 18;140(10):786-94
https://www.ncbi.nlm.nih.gov/pubmed/15148065  (metabolic effects of rosiglitazone for lipodystrophy)

Mauss S et al. AIDS. 2003 Jan 24;17(2):189-94
https://www.ncbi.nlm.nih.gov/pubmed/12545078 (Differentiating hyperlipidaemia associated with antiretroviral therapy)

Back to top

2004 (Washington)

Falutz J et al. AIDS. 2005 Aug 12;19(12):1279-87
https://www.ncbi.nlm.nih.gov/pubmed/16052083 (first tesamorelin randomized controlled trial)

Hertel J et al. J Biol Chem. 2004 Dec 31;279(53):55147-52. Epub 2004 Oct 20
https://www.ncbi.nlm.nih.gov/pubmed/15496402 (mechanism for PI effect on insulin resistance)

Mallon PW et al. J Infect Dis. 2005 May 15;191(10):1686-96. Epub 2005 Apr 12
https://www.ncbi.nlm.nih.gov/pubmed/15838796 (in vivo study showing mechanisms of mitochondrial toxicity and lipoatrophy)

Back to top

2005 (Dublin)

Sutinen J etal. Antivir Ther. 2007;12(1):97-105.
https://www.ncbi.nlm.nih.gov/pubmed/17503753 (randomized controlled trial of Uridine for LA)

Diop ME et al. AIDS Res Hum Retroviruses. 2006 Dec;22(12):1242-7
https://www.ncbi.nlm.nih.gov/pubmed/17209766 (first study showing inaccuracy of  A1c in HIV)

Nolan D et al. Antivir Ther. 2003 Dec;8(6):617-26
https://www.ncbi.nlm.nih.gov/pubmed/14760896 (contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy)

Mauss S et al. AIDS. 2005 Jan 3;19(1):93-5
https://www.ncbi.nlm.nih.gov/pubmed/15627039 (antiretroviral therapy with tenofovir is associated with mild renal dysfunction)

Back to top

2006 (San Francisco)

Grunfeld C et al. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):283-90
https://www.ncbi.nlm.nih.gov/pubmed/18167644 (VAT and upper trunk SAT are independently associated with insulin resistance)

Hadigan C et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4438-44. Epub 2006 Aug 29
https://www.ncbi.nlm.nih.gov/pubmed/16940448 (inhibiting lipolysis improves glucose and TGs)

WandH et al. AIDS. 2007 Nov 30;21(18):2445-53
https://www.ncbi.nlm.nih.gov/pubmed/18025881 (metabolic changes with ART initiation-INITIO study)

Back to top

2007 (Sydney)

Grunfeld C et al. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):283-90
https://www.ncbi.nlm.nih.gov/pubmed/19667106  (nevirapine and lipid effects)

Kingsley LA et al. AIDS. 2008 Aug 20;22(13):1589-99. doi: 10.1097/QAD.0b013e328306a6c5
https://www.ncbi.nlm.nih.gov/pubmed/18670218  (subclinical CVD and ART)

Worm SW et al. Circulation. 2009 Feb 17;119(6):805-11. doi: 10.1161/CIRCULATIONAHA.108.790857. Epub 2009 Feb 2
https://www.ncbi.nlm.nih.gov/pubmed/19188509 (Diabetes and CVD in D:A:D)

Young J et al. J Clin Epidemiol. 2009 Jun;62(6):632-41. doi: 10.1016/j.jclinepi.2008.07.015. Epub 2008 Dec 23
https://www.ncbi.nlm.nih.gov/pubmed/19108985 (modelling risk to develop metabolic syndrome based on antiretrovirals used)

Yarasheski KE et al. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E243-51. doi: 10.1152/ajpendo.00468.2010. Epub 2010 Oct 19
https://www.ncbi.nlm.nih.gov/pubmed/20959530  (Pioglitazone as a treatment option)

Kosmiski LA et al. J Clin Endocrinol Metab. 2008 Jan;93(1):216-24. Epub 2007 Oct 16 https://www.ncbi.nlm.nih.gov/pubmed/17940113 (lipodystrophy and adipokines in FRAM)

Back to top

2008 (London, 10th Workshop)

Grund B et al. AIDS. 2009 Jul 31;23(12):1519-29. doi: 10.1097/QAD.0b013e32832c1792
https://www.ncbi.nlm.nih.gov/pubmed/19531929 (ART related to drop in BMD: SMART)

Jacobson DL et al. AIDS. 2010 Mar 13;24(5):687-96. doi: 10.1097/QAD.0b013e328336095d
https://www.ncbi.nlm.nih.gov/pubmed/20168204 (decrease peak bone mass in HIV+ boys vs HIV-)

Triant VA et al. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):268-73. doi: 10.1097/QAI.0b013e3181a9992c
https://www.ncbi.nlm.nih.gov/pubmed/19387353 (association and interaction of HIV and CRP on MI risk)

Mauss S et al. Antivir Ther. 2008;13(8):1091-5
https://www.ncbi.nlm.nih.gov/pubmed/19195336 (cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients)

Mauss S et al. HIV Med. 2008 Jul;9(6):415-20. doi: 10.1111/j.1468-1293.2008.00574.x. Epub 2008 May 4
https://www.ncbi.nlm.nih.gov/pubmed/18459949 (Lipoprotein(a) in patients initiating antiretroviral therapy)

Back to top

2009 (Philadelphia)

Brown TT et al. Diabetes Care. 2010 Oct;33(10):2244-9 doi: 10.1161/ATVBAHA.109.192088 https://www.ncbi.nlm.nih.gov/pubmed/20664016 (systemic inflammation after ART initiation associated with DM)

Lo J et al. JAMA. 2008 Aug 6;300(5):509-19 doi: 10.1001/jama.300.5.509
https://www.ncbi.nlm.nih.gov/pubmed/18677023 (low dose GH decreases VAT)

Capeau J et al. AIDS. 2012 Jan 28;26(3):303-14. doi: 10.1097/QAD.0b013e32834e8776
https://www.ncbi.nlm.nih.gov/pubmed/22089377 (diabetes risk over time in HIV+ in France)

Back to top

2010 (London)

Bastard JP et al. Antivir Ther. 2012;17(5):915-9. doi: 10.3851/IMP2093. Epub 2012 Mar 21
https://www.ncbi.nlm.nih.gov/pubmed/22436412  (very low-level viremia associated with inflammation)

Viard JP et al. AIDS. 2011 Jun 19;25(10):1305-15. doi: 10.1097/QAD.0b013e328347f6f7
https://www.ncbi.nlm.nih.gov/pubmed/21522006  (vitamin D deficiency and AIDS events in EuroSIDA)

Hernandez-Vallejo SJ et al. Aging Cell. 2013 Dec;12(6):955-65. doi: 10.1111/acel.12119. Epub 2013 Jul 19
https://www.ncbi.nlm.nih.gov/pubmed/23795945 (effect of PIs on osteoblast differentiation and cellular senescence)

Back to top

2011 (Rome)

Bedimo R et al. AIDS. 2012 Apr 24;26(7):825-31. doi: 10.1097/QAD.0b013e32835192ae
https://www.ncbi.nlm.nih.gov/pubmed/22301411  (first paper to show that TDF is associated with fracture)

Calvo-Sánchez M et al. HIV Med. 2013 Jan;14(1):40-8. doi: 10.1111/j.1468-1293.2012.01057.x. Epub 2012 Oct 22.
https://www.ncbi.nlm.nih.gov/pubmed/23088307  (differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to ACS)

Boccara F et al. Eur Heart J. 2011 Jan;32(1):41-50. doi: 10.1093/eurheartj/ehq372. Epub 2010 Oct 21.
https://www.ncbi.nlm.nih.gov/pubmed/20965887  (secondary CVD prevention in HIV)

Back to top

2012 (Washington)

Borges ÁH et al. AIDS. 2013 Jun 1;27(9):1433-41. doi: 10.1097/QAD.0b013e32835f6b0c
https://www.ncbi.nlm.nih.gov/pubmed/23945504 ( shows relationship between inflammation and incident cancer)

Schouten J et al. Clin Infect Dis. 2014 Dec 15;59(12):1787-97. doi: 10.1093/cid/ciu701. Epub 2014 Sep 2
https://www.ncbi.nlm.nih.gov/pubmed/25182245 (cross-sectional study of comorbidity prevalence in HIV+ vs HIV- in AgeHIV)

Randell P et al. Antivir Ther. 2017;22(2):145-151. doi: 10.3851/IMP3098. Epub 2016 Oct 6
https://www.ncbi.nlm.nih.gov/pubmed/27708251 (health volunteer study showing worse metabolic/inflammatory effects of RAL vs PI)

Back to top

2013 (Brussels, 15th Workshop)

Raggi P et al. J Cardiovasc Comput Tomogr. 2015 Nov-Dec;9(6):553-8. doi: 10.1016/j.jcct.2015.08.002.
https://www.ncbi.nlm.nih.gov/pubmed/26310588 (epicardial fat and MI)

Young J et al. HIV Med. 2014 Sep;15(8):505-10. doi: 10.1111/hiv.12149
https://www.ncbi.nlm.nih.gov/pubmed/24641488 (recovery of GRF after TDF discontinuation)

Friis-Møller N et al. Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291 https://www.ncbi.nlm.nih.gov/pubmed/25882821 (updated DAD CVD risk equation)

Kooij KW et al. J Infect Dis. 2015 Feb 15;211(4):539-48. doi: 10.1093/infdis/jiu499. https://www.ncbi.nlm.nih.gov/pubmed/25180239 (reduced bone mineral density (BMD) observed in younger men having sex with men (MSM), regardless of HIV-status)

Back to top

2014 (Philadelphia)

Best C et al. J Clin Endocrinol Metab. 2015 Jul;100(7):2621-9. doi: 10.1210/jc.2015-1531 https://www.ncbi.nlm.nih.gov/pubmed/25938633 (sitagliptin randomized controlled trial)

O’Halloran JA et al. HIV Med. 2015 Nov;16(10):608-19. doi: 10.1111/hiv.12270 https://www.ncbi.nlm.nih.gov/pubmed/26111187 (effect of ART initiation on endothelial and platelet function)

Dubé MP et al Clin Infect Dis. 2015 Sep 1;61(5):840-9. doi: 10.1093/cid/civ385 https://www.ncbi.nlm.nih.gov/pubmed/25979307 (randomized controlled trial - niacin vs fenofibrate)

van Zoest RA et al. Clin Infect Dis. 2016 Jul 15;63(2):205-13. doi: 10.1093/cid/ciw285 https://www.ncbi.nlm.nih.gov/pubmed/27143668 (more hypertension in HIV related to body composition changes and prior d4T use)

Back to top

2015 (Barcelona)

Mudd JC et al. J Infect Dis. 2016 Dec 15;214(12):1808-1816. Epub 2016 Oct 4 https://www.ncbi.nlm.nih.gov/pubmed/27703039  (identify a T-cell phenotype that may be important in CVD pathogenesis in HIV)

Morris A et al. AIDS. 2017 Feb 20;31(4):539-544. doi: 10.1097/QAD.0000000000001365. https://www.ncbi.nlm.nih.gov/pubmed/27941393 (rosuvastatin in HIV COPD)

Hoy JF et al. J Bone Miner Res. 2017 Sep;32(9):1945-1955. doi: 10.1002/jbmr.3183 https://www.ncbi.nlm.nih.gov/pubmed/28650589 (START Bone)

Back to top

2016 (New York City)

Sharma A et al. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):441-449. doi: 10.1097/QAI.0000000000001692
https://www.ncbi.nlm.nih.gov/pubmed/29940603 (one of the first TBS studies in HIV)

van Zoest RA et al. Eur J Prev Cardiol. 2017 Aug;24(12):1297-1307. doi: 10.1177/2047487317714350
https://www.ncbi.nlm.nih.gov/pubmed/28578613 (CVD risk prevention in Age HIV

Koethe JR et al. J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):e14-e21. doi: 10.1097/QAI.0000000000001573 https://www.ncbi.nlm.nih.gov/pubmed/29040163  (activated T cells in adipose tissue in HIV)

van Zoest Eur J Prev Cardiol. 2017 Aug;24(12):1297-1307. doi: 10.1177/2047487317714350
https://www.ncbi.nlm.nih.gov/pubmed/28578613 (suboptimal primary and secondary CVD prevention in PLWH on ART)

Mauss S et al. Antivir Ther. 2017;21(1):81-88. doi: 10.3851/IMP3094
https://www.ncbi.nlm.nih.gov/pubmed/27685337 (effect of antiviral therapy for HCV on lipid levels)

Back to top

2017 (Milan)

Hoy JF et al. J Bone Miner Res. 2017 Sep;32(9):1945-1955. doi: 10.1002/jbmr.3183
https://www.ncbi.nlm.nih.gov/pubmed/28650589 (findings from the START Bone Mineral Density Substudy)

Back to top